Advertisement

Nanoscale Research Letters

, 13:231 | Cite as

Recent Status of Nanomaterial Fabrication and Their Potential Applications in Neurological Disease Management

  • Khwaja Salahuddin Siddiqi
  • Azamal Husen
  • Sayed Sartaj Sohrab
  • Mensur Osman Yassin
Open Access
Nano Review

Abstract

Nanomaterials (NMs) are receiving remarkable attention due to their unique properties and structure. They vary from atoms and molecules along with those of bulk materials. They can be engineered to act as drug delivery vehicles to cross blood-brain barriers (BBBs) and utilized with better efficacy and safety to deliver specific molecules into targeted cells as compared to conventional system for neurological disorders. Depending on their properties, various metal chelators, gold nanoparticles (NPs), micelles, quantum dots, polymeric NPs, liposomes, solid lipid NPs, microparticles, carbon nanotubes, and fullerenes have been utilized for various purposes including the improvement of drug delivery system, treatment response assessment, diagnosis at early stage, and management of neurological disorder by using neuro-engineering. BBB regulates micro- and macromolecule penetration/movement, thus protecting it from many kinds of illness. This phenomenon also prevents drug delivery for the neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis, amyotrophic lateral sclerosis, and primary brain tumors. For some neurological disorders (AD and PD), the environmental pollution was considered as a major cause, as observed that metal and/or metal oxide from different sources are inhaled and get deposited in the lungs/brain. Old age, obesity, diabetes, and cardiovascular disease are other factors for rapid deterioration of human health and onset of AD. In addition, gene mutations have also been examined to cause the early onset familial forms of AD. AD leads to cognitive impairment and plaque deposits in the brain leading to neuronal cell death. Based on these facts and considerations, this review elucidates the importance of frequently used metal chelators, NMs and/or NPs. The present review also discusses the current status and future challenges in terms of their application in drug delivery for neurological disease management.

Keywords

Nanomaterials/nanoparticles Nanomedicines Biomedical application Drug delivery Health and safety 

Abbreviations

AD

Alzheimer’s disease

ALS

Amyotrophic lateral sclerosis

APP

Amyloid precursor protein

Amyloid-β

BBB

Blood-brain barrier

CNS

Central nervous system

CNT

Carbon nanotube

DHA

Docosahexaenoic acid

FDA

Food and Drug Administration

LCs

Liquid crystals

MEs

Microemulsions

MS

Multiple sclerosis

MPs

Microparticles

MSCs

Mesenchymal stem cells

NFT

Neurofibrillary tangles

NMs

Nanomaterials

NPs

Nanoparticles

PBCA

Poly (butyl cyanoacrylate)

PD

Parkinson’s disease

PLGA

Poly(d,l-lactic-co-glycolic acid)

ROS

Reactive oxygen species

SLN

Solid lipid nanoparticle

SOD

Superoxide dismutase

SWCNTs

Single-walled carbon nanotubes

Review

Background

Nanomaterials (NMs) are expressed as materials having typical sizes in the range of 1–100 nm. Basically, they are composite-based (combine NMs with other NMs or with larger, bulk-type materials), dendrimer-based (nanosized polymers built from branched units), carbon-based (fullerenes, nanotubes), and metal-based (quantum dots, nanosilver, nanogold, and metal oxides viz. cerium oxide, titanium oxide, iron oxide, and zinc oxide) materials. In this cutting-edge century, fabrication of these nanoparticles (NPs), one by one or cluster, with desired particle size and shapes led to many promising applications in drug-gene delivery, disease management, pharmaceuticals, cosmetics, food, photonic crystals, coatings, paints, catalysis, bioremediation, material science, plant growth, and/or their production and protection [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12].

The use of NMs at commercial and industrial levels has considerably increased, for instance about 3000 tons of TiO2 NPs per year was produced [13] and more than 50% was used in personal care products such as sunscreens [14]. Likewise, silver and gold NPs have been extensively used in medicine, disease diagnostic, sensor technology, biological leveling, pharmaceuticals, and many other biomedical applications [2, 11, 15, 16, 17, 18]. Depending on their magnetic properties, iron and iron oxide NPs have been widely employed for cancer treatment, drug delivery, MRI, catalysis, and removal of pesticides from potable water system [11]. Platinum NPs are used as antioxidants and catalysts [10, 19], while palladium NPs are widely applied as catalysts and in cancer therapy [10].

In recent years, these NMs are being used as nanomedicines and play a vital role in diagnosis and treatment of numerous neurological disorders globally. Thus, nanomedicine is an emerging field where engineered NMs are utilized for the detection, treatment, and prevention of multiple diseases including neurological disorders. Nanomedicines are made up of nanoscale molecules with higher drug bioavailability. Often, NMs are designed to not interact with body defense mechanisms. The NMs are smaller in size and they can easily be stored into peripheral tissues for longer period availability in the body [20]. NMs can interact with physiological systems at the molecular and supra molecular level. They can be redesigned to respond against cell milieu and trigger desired biological activities in cell and tissue with reduced adverse effect. The novel nanotechnological inventions are making a valuable therapeutic contribution into the treatment and reduction of life-threatening diseases along with the neurological disorders [21].

Almost all neurological disorders are associated with the central and peripheral nervous systems. The brain, spinal cord, and nerves control the entire working of the body system. If anything goes incorrect with the nervous system, subsequently, problems related to speaking, swallowing, breathing, learning, etc. are commonly detected. The neurological disease treatment and management options are very limited because of the blood-brain barrier (BBB) which restricts the crossing and poor solubility of therapeutic molecules and desired drugs by the oral route. To overcome this issue, nanotechnology has provided an opportunity in novel technological inventions in the form of nanotubes, nanowires, nanospheres, robots, miniatures, nanosuspensions, nanomedicines, nanogels, nanoemulsions, nanocarriers, microparticles (MPs), NPs, polymeric and solid lipid NPs (SLNs), solid lipid carriers, liquid crystals (LCs), liposomes, microemulsions (MEs), and hydrogels for the effective and targeted drug delivery system and various disease diagnosis and management [22].

Currently, continuous efforts are being made by various research groups working on the neurological disorders in developing nanomedicines for targeted drug delivery by using NMs for the effective control and management of neurological disorders. Most frequently reported neurological disorders are Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), neurological tumors, and ischemic stroke [23]. Among these, AD is categorized by loss of memory, loss of lexical access, and judgment impairment. It is an age-related disorder and increases with advancing age (60–85 years). Beside old age, obesity, diabetes, and cardiovascular disease are major factors for rapid deterioration of human health and on onset of AD. Mutations of genes have been described to cause the early onset familial forms of AD and they are known for coding amyloid precursor protein (APP) on chromosome 21 [24], presenilin 1 (PS1) on chromosome 14 [25], and presenilin 2 (PS2) on chromosome 1 [26]. The late onset sporadic form of AD embodies more than 90% of all diseases. The etiology of disease doubles each year after the age of 65 and reaches 50% at 85 years of age [27]. The genetic risk for the sporadic form of AD is due to inheritance of ε4 allele of apolipoprotein E which is located on chromosome 19q13 [27]. This protein can affect the progression of the disease and the extent of neurological cell damage [27, 28]. In view of this, numerous mechanisms have been postulated to elucidate the influence of apolipoprotein E in Alzheimer’s disease patients’ brain [28]. This protein also has a risk factor for the growth of mild cognitive impairment (MCI) which may later convert to AD development [29]. AD contributes in more than 80% of dementia and now it has been categorized as the most devastating disease in the world [20, 30, 31, 32]. Environmental pollution is the major cause of AD and PD progression. Metal and metal oxide from different sources are inhaled and get deposited in the lungs/brain. For instance, CeO2 and TiO2 have demonstrated accumulation in tissues after long-term exposure [33, 34]. It has been verified that TiO2 NPs induced PD-like symptoms in zebrafish larvae and PC 12 cell lines. It induced premature hatching and disturbed their locomotion [35]. The TiO2 NPs in the brain tissues of zebrafish have been shown to induce ROS generation leading to cell death in the hypothalamus region. These NPs also affect the neuron function. In a recent study, Yoo et al. [36] have demonstrated that gold NPs enable the generation of induced dopamine neurons for PD treatment in the presence of electromagnetic fields.

As mentioned, the bioavailability and effective delivery of drugs and other therapeutic compounds in the nervous system is restricted by two barriers namely BBB and blood cerebrospinal fluid barrier (BCSFB) [20, 37, 38, 39, 40]. The BBB plays a significant role to protect the entry of blood-borne pathogens like bacteria, virus, parasites, and toxins [41]. Although the BBB facilitates a shield to the brain, it also interferes with the treatment of the numerous neurological disorders. It is therefore essential to develop a benign and effective drug delivery system which may cross the BBB and reach the target cells without producing any adverse effects. Vashist et al. [42] have reported that the BBB decreased concentration of drug that reaches the site of action and decreased its ability to treat the target disease; thus, higher concentration of drugs strengthened the need to develop nanomaterial-based drug delivery systems. The study also highlighted the recent trends of nanogel preparation and their significance in drug delivery system. It is important to note that either lipophilic molecules or low molecular weight molecules (below 400–600 Da) cross the BBB; thus, caution of drug selection is required for neurological disorder treatments. AD may be familial or sporadic, cognitive impairment, and plaque deposits in the brain leading to neuronal cell death. It is advisable to prevent the loss of functional neurons or to replace damaged neurons. Transplantation of neural stem cells (NSC) has been revealed to improve the cognition and synaptic conductivity in animal model of AD [43].

Zhang et al. [44] have reported the significance of NMs in stem cell therapy for several kinds of neurological diseases. The authors found that the NM promotes stem cell proliferation and differentiation both in vivo and in vitro, as well as contributes dominant roles in stem cell imaging and tracking. Trekker et al. [45] have also reported the significance of mesenchymal stem cells (MSCs) to treat ischemic stroke; however, their systematic delivery to the target remains a challenge. MSCs labeled with dextran-coated MNPs were disseminated in the brain to areas of enhanced cerebral lesion risk and revealed better functional recovery. The study reported that even though the intravenous administration routes were benign, the amount of MSCs that crossed the BBB was limited.

In this review, the main emphasis has been given on the frequently used metal chelators, NMs/NPs, and the current status in terms of their application in drug delivery system for neurological disease management.

Neurological Disorders and Management

Taken together, the CNS-associated main challenges are absence of smart diagnostic tools and incapability of effective drugs to cross BBB. To overcome these issues, various formulations of NMs/NPs have shown extensive and promising applications in drug delivery against neurological disorder treatment and management (Fig. 1). The specific application of NMs/NPs in neurological disorders like AD, PD, ALS, MS, neurological tumors, and ischemic stroke is given below.
Fig. 1

Different types of NPs and their application in neurological disorder treatment and management

Alzheimer’s Disease

Currently, AD has affected more than 35 million people and it is expected that by 2050 the cases will increase [22] at global level. At present, AD treatment is based on symptoms and vascular prevention by using cholinesterase inhibitors and N-methyl-D-aspartate antagonists. The use of nanotechnology in AD diagnosis and treatment has shown promising results. Multiple NMs are being used in AD diagnosis and treatment. Many methods have been utilized to prepare NPs such as polymer polymerization, ionic gelation emulsion, solvent evaporation, solvent diffusion, nanoprecipitation, spray drying, and particle replication in non-wetting templates. The condition of AD can be improved by using NPs which have a good affinity with the amyloid-β (Aβ) forms which induces “sink effect.” The diagnosis of AD and detection of Aβ1 has reached an advanced stage by using ultrasensitive NP-based bio-barcodes, immune sensors, and scanning microscopy procedures [46].

The main focus of the treatment is to target the metabolic dysfunction and aggregation of proteins and Aβ peptides. Plaque formation from Aβ protein is shown in Scheme 1 below:
Scheme 1

Plaque formation from amyloid-β protein

The intracellular hyperphosphorylated neurofibrillary tangles and amyloid plaques (extracellular deposits of Aβ peptide) in the brain are the main cause of AD. Other reasons of AD progression have also been suggested, namely dysregulation of the cholinergic system and Aβ peptide deposition in the brain [31]. NFTs damage axonal integrity and neurotransmitter transport [47]. A drug should therefore be formulated with significant characters that can cross the BBB. The BBB protects the brain against variable pathogens. Lipophilic molecules, O2 and CO2, and other molecules with a molecular weight < 600 g/mol can easily diffuse across BBB. Amino acids, glucose, and insulin enter into the brain through specific receptor-mediated endocytosis [48]. Many devices have been developed by using multiple approaches in drug transportation to cross BBB and reach into the brain tissue of AD patients. One such approach is the conjugation of active compounds with nanocarriers viz. polymeric micelles, liposomes, lipid, and polymeric NPs having high association to BBB. Thus, the nanocarrier interaction with brain nutrient transport system allows the drug to reach the target site. For instance, Lockman et al. [49] have reported that the coating of NPs with thiamine is targeting the particles to BBB thiamine transporter. The drug is thus transported through BBB [50]. Biodegradable materials as a carrier are helpful in transporting the drug to the site of use. These treatments are expected to protect, repair, and regulate the damage in central nervous system (CNS) tissues [51].

The hydrophilic, charged, fluorescent marker ThT has been used as a probe for the detection of amyloid-β plaques of AD [52]. Hartig et al. [53] have delivered the encapsulated ThT NPs containing PBCA into the mice brain by intrahippocampal injection. In the study, TEM images have shown the presence of NPs in the microglia and neurons. The detection of AD can therefore be done by using this technique.

Biochemical investigation of the brain of AD patients has shown neocortical deficits in choline acetyltransferase [54] which is accountable for the acetylcholine (Ach) synthesis. It is also helpful in learning and sharpening of memory. It is therefore anticipated that generation of cholinergic neurons in the basal forebrain and loss of neurotransmission in the cerebral cortex contribute to the deterioration in cognitive function in patients suffering from AD. Treatment of rat with scopolamine, a ACh muscarinic receptor antagonist, reduced the levels of ACh with concurrent impairment of spatial memory [55]. However, it has been observed that substances which increase ACh release, viz. linopirdine, improve atropine-persuaded memory loss [56].

Polymeric NPs were made and encapsulated with radio-labeled 125I-clioquinol to enhance its transport to the brain and amyloidβ plaque retention of 125I-CQ. These NPs have been observed to be a suitable vehicle for in vivo single-photon emission computed tomography [22, 57]. Another NP known as magnetic iron oxide is being utilized efficiently as it has bigger surface area and magnetic effects with less toxicity. Gold NPs have been utilized as a valuable tool in kinetic studies for Aβ peptide aggregation. Additionally, heterodimeric NPs were synthesized by fusing gold NPs containing a cobalt(II) magnetic core and a platinum shell. These NPs were stabilized by coating with lipoic acid-PEG and showed promising result in AD [58]. Additionally, SLNs are typically spherical lipid core matrix which can efficiently solubilize lipophilic molecules. The SLNs can cross the BBB and drugs/therapeutic molecules could be efficiently delivered into the brain by endocytosis [22, 59].

Liposomes are another type of drug delivery vehicles and contain one or more phospholipid bilayers to carry lipophilic or hydrophilic drugs. The rivastigmine liposomes and cell-penetrating peptide-modified liposomes were formulated for improved distribution into the brain and reduced the side effect resulting into enhanced pharmacodynamics. The results showed that rivastigmine concentration across the BBB were higher after 8 h of delivery into the brain [60]. The surfactant-based drug delivery systems provided another option for drug delivery by aggregation of surfactant molecules in the presence of water to form structures based on the surfactant concentration, presence of salts, and temperature. The MEs are usually thermodynamically stable. Thus, microemulsion, nanoemulsions, and lyotropic LC mesophases can be generated with diverse geometries [22].

Two types of NPs such as polysorbate 80-coated poly (n-butyl cyanoacrylate) and another coated with polysorbate 80 were fabricated using emulsion polymerization to treat AD [61]. A dual functional NP was developed for delivery of drug based on PEGylated poly (lactic acid) polymer with two targeting peptides, TGN (a ligand composed of 12 amino acids: TGNYKALHPHNGC) and QSH (d D-enantiomeric peptide: QSHYRHISPAQVC) by conjugating at the surface of NPs and used in cases of AD [62]. TGN was used for targeting BBB ligands while QSH has effective association for Aβ plaques. These NPs were directly sent to Aβ plaques by targeted delivery in the brains of AD mice. Thus, it is expected that the use of NPs could be an important tool for AD diagnosis and treatment [22].

Postmortem studies of brain tissues from AD patients had indicated two types of lesions, namely senile plaques (SPs) and neurofibrillary tangles (NFTs). SPs in AD patient brain have been found to be augmented with copper, zinc, and iron. It is thought that the metals interact with metals and proteins which may influence aggregation of amyloid-β (Aβ) causing toxicity. Zinc, copper, and iron have been revealed from several clinical investigations, to be supplemented in Aβ plaques in transgenic mice [63, 64, 65, 66]. Zinc and iron have been detected in NFT-containing neurons. Iron (III) and Cu (II) can chelate with proteins and alter their basic conformation promoting phosphorylation and aggregation. Metals have preference to bind with various atoms in proteins such as N, O, and S. Thus, metal chelates may be used in the treatment of AD and the excess metals in SPs may be removed by coordination with proteins. Aβ reduces copper (II) and iron (III) ions and produces H2O2 by double electron transfer to O2 [66].
$$ 2{\mathrm{H}}_2{\mathrm{O}}_2\to 2{\mathrm{H}}_2\mathrm{O}\kern0.5em +\kern0.5em {\mathrm{O}}_2 $$
This Aβ-induced oxidative stress and toxicity in cell culture is moderately arbitrated by methionine and tyrosine [67, 68]. Free radical-mediated reactions play a significant role in aging and physiology of many neurological diseases. Antioxidants such as polyphenolic compounds (resveratrol, curcumin, catechins) are found to be very helpful in AD treatment [69]. These compounds exhibit potent antioxidative and anti-inflammatory properties (Table 1), and numerous in vitro investigations have exhibited that green tea polyphenols could protect neuron from Aβ-induced damages [70, 71, 72]. Green tea polyphenols have exhibited positive influence in animal models of stroke/cerebral ischemia, AD, and PD. Green tea contains epigallocatechin gallate (EGCG) as an active ingredient that acts as a neuroprotectant against Aβ.
Table 1

The beneficial role of selected polyphenolic compounds in Alzheimer’s disease

Polyphenolic compounds

Target and role

Properties

Key references

Resveratrol

Aβ pathway

Remodels soluble oligomers and fibrils form into nontoxic form of Aβ

Ladiwala et al. [73]

Aβ pathway

Reduction of production of Aβ peptides in vitro

Marambaud et al. [74]

Cytoprotection

Protect cells from Aβ-induced toxicity

Han et al. [75]

Oxidative markers

Decrease of ROS and lipid peroxide levels in animal models

Haque et al. [76]

Synaptic density

Decrease of cognitive deficits in animal models

Kumar et al. [77]

Specific proteins

Reduced the number of lysosomes and Aβ-induced toxicity

Regitz et al. [78]

Mitophagy pathway

Reduced apoptosis, decreased oxidative status, and alleviated mitochondrial damage in Aβ1–42-treated PC12 cells

Wang et al. [79]

Inhibiting the increase of protein kinase A and activation of PI3K/Akt signaling pathway

Alleviates Aβ25–35-induced dysfunction in hippocampal CA1 pyramidal neurons via recovery of the function of transient potassium channel and delay rectifier potassium channel by inhibiting the increase of protein kinase A and the activation of PI3K/Akt signaling pathway

Yin et al. [80]

Curcumin

Aβ pathway

Reduction of BACE-1 mRNA

Liu et al. [81]

Aβ pathway

Reduction of the formation of Aβ fibrils

Ono et al. [82]

Aβ pathway

Reduction of Aβ deposits and senile plaques in Tg2576 mice model

Yang et al. [83]

Garcia-Alloza et al. [84]

Lim et al. [85]

Frautschy et al. [86]

Cytoprotection

Protect cells from Aβ-induced toxicity

Kim et al. [87]

Inflammatory pathways

Reduction of Aβ-induced expression of cytokines and chemokines

Lim et al. [85]

Synaptic density

Increase of post-synaptic density-95 in vitro in the brain of Aβ-injected rats

Frautschy et al. [86]

Cognitive deficits

Decrease of cognitive deficits in animal models

Frautschy et al. [86]

Ishrat et al. [88]

Catechins

Aβ pathway

Reduction in the translation of APP mRNA

Levites et al. [71]

Aβ pathway

Increase α-secretase activity; reduction in the production of Aβ peptides in APP695 over-expressing neurons

Rezai-Zadeh et al. [89]

Aβ pathway

Reduction in β-secretase activity

Jeon et al. [90]

Aβ pathway

Reduction in the formation of Aβ fibrils by binding to the native unfolded Aβ

Levites et al. [71]

Ehrnhoefer et al. [91]

Bieschke et al. [92]

Cytoprotection

Protect cells from Aβ-induced toxicity

Levites et al. [71]

Bieschke et al. [92]

Cytoprotection

Reduction in Aβ-induced caspase activity in hippocampal neuronal cells

Choi et al. [70]

Inflammatory pathways

Reduction in Aβ-induced cytokines in human astrocytoma U373MG cells

Kim et al. [93]

Oxidative markers

Reduction in Aβ-induced levels of lipid oxidation in hippocampal neuronal cells

Choi et al. [70]

Cognitive deficits

Decrease of cognitive deficits in animal models

Rezai-Zadeh et al. [89]

Haque et al. [76]

Curcumin, an active component found in turmeric, works as a potent antioxidative and anti-inflammatory agent. When it was fed to aged Tg2576 mice, significant reduction of Aβ level and plaques was observed [83]. It also blocked Aβ aggregation and fibril formation in vitro (IC50 = 0.8 μM) which reduced amyloid plaques [83]. Curcumin possibly chelates the redox-active iron and copper [94]. Since its solubility in water is very low with rapid systemic elimination, low absorption, and degradation at alkaline pH, it is safe even at higher doses [95, 96]. Yang et al. [96] have reported that 10 mg kg−1 of curcumin given intravenously to rat yielded maximum serum curcumin level of 0.36 ± 0.05 μg ml−1, while a 50-fold higher oral curcumin dose gave only 0.06 ± 0.01 μg ml−1 serum level. However, Ravindranath and Chandrasekhara [97] have reported that the higher dose did not result in higher absorption. The drug molecules that are not ionized at physiological pH are lipophilic with low molecular mass and can cross BBB by diffusion. Neuropeptides, amino acids, and hexoses normally require a specific carrier to diffuse into the brain [98] although peptides and proteins can cross the BBB by saturable transport system [99].

Polymeric nanocarriers are promising candidates because they can open the tight junctions (Tjs) of BBB, prolong the drug release, and protect them against enzymatic degradation [41]. Hydrophilic NPs with less than 100 nm are very effective drug carriers. Bio-distribution increases with decreasing size of NPs. The distribution of the injected gold NP (15, 50, and 100 nm) in mice showed higher amount of NP with 15-nm particle size in the stomach, brain, heart, lung, liver, spleen, kidney, and blood. The larger particles are absorbed in a smaller amount in the stomach, pancreas, brain, and blood [100]. A number of factors are responsible for rapid transport of therapeutic drugs/molecules across BBB, for instance, molecular mass of drug, molecular charge, structural conformation, concentration gradient solubility, polymer used, and affinity of the drug to bind with certain donor sites/cellular proteins [101]. The nonappearance of toxicity at the BBB both in vitro and in situ suggests that the NPs may be transported via the barrier by endocytosis/transcytosis or even through diffusion. They may be taken up by brain endothelial cells [102]. It is, however, essential to examine the toxicity of the NP prior to its use as carrier. Drug-loaded NPs tested for the treatment of AD have been summarized in Table 2.
Table 2

Types of NPs and/or NMs for Alzheimer’s disease treatment

Type of NPs and/or NMs

Size

Drugs

Advantage and/or application

Key references

Polymeric NPs

1–1000 nm

Neuroprotective peptide, rivastigmine, curcumin, estradiol, S14G-humanin, anti Aβ antibody, fibroblast growth factor, Aβ-targeting peptide, iron chelator, selegiline, Aβ 1–15, ROCKII-siRNA, clioquinol

Drug-loaded NPs exhibited specificity for Aβ plaques both in vitro and in vivo; capable of aiding in the early diagnosis of Alzheimer’s disease

Hadavi and Poot [32]

Sahni et al. [103]

Gregori et al. [104]

Wen et al. [105]

Liposomes, CPP-modified liposomes, flexible liposomes

200–500 μm

Curcumin, phosphatidic acid, cardiolipin, XO4, glycofused benzopyrane, anti Aβ antibody, ZnAc, EDTA, His, epigallocatechin-3-gallate, quercetin, rivastigmine HCl, galantamine

Beneficial for stabilizing therapeutic compounds, overcoming obstacles to cellular and tissue uptake, and improving bio-distribution of compounds to target sites in vivo. Present as an attractive delivery system due to their flexible physicochemical and biophysical properties, which allow easy manipulation to address different delivery considerations

Hadavi and Poot [32]

Gregori et al. [104]

Wen et al. [105]

Sercombe et al. [106]

Solid lipid NPs and lipid-coated microbubble/NP-derived (LCM/ND)

50–1000 nm

Piperine, galantamine, lipoyl-memantine, rivastigmine HCl

Stabilizing drugs that suffer from physicochemical or biological instability; improving the bioavailability of drugs that cross the BBB; increasing permeating of drugs through the BBB

Wen et al. [105]

Qu et al. [107]

D’Arrigo [108]

Chitosan NPs

15–200 nm

Tacrine, Aβ fragment,

Enhanced concentration of drug in the brain, more stable, permeable, and bioactive

Sahni et al. [103]

Gregori et al. [104]

Wen et al. [105]

Ahmed et al. [109]

Magnetite NPs

1 nm to 5 μm

Tacrine

Useful as selective biomarkers for detecting the location and the removal of other amyloid plaques derived from different amyloidogenic proteins

Sahni et al. [103]

Gregori et al. [104]

Busquets et al. [110]

Sara Teller et al. [111]

Chen et al. [112]

Albumin NPs

40–500 nm

Apo-E binding, tacrine

Enhanced brain uptake of NPs by cerebral endothelium, by an endocytic mechanism, followed by transcytosis into the brain parenchyma

Sahni et al. [103]

Gregori et al. [104]

Saraiva et al. [113]

Karimi et al. [114]

Gold NPs

1–150 nm

Aβ-binding peptide

The prepared NPs dissolve toxic protein deposits of Aβ1–42 (amyloid deposits) by the combined use of weak microwave fields and gold NPs without any bulk heating

Hadavi and Poot [32]

Sahni et al. [103]

Gregori et al. [104]

Gao et al. [115]

Exosomes

30–100 nm

BACE1-siRNA

Exosomes penetrate the blood-brain barrier and deliver drugs to the brain. They can be strategically engineered to carry drugs and possess a suitable half-life for many diseases

Gregori et al. [104]

Sarko et al. [116]

Quek et al. [117]

Chen et al. [118]

Jiang and Gao [119]

Polystyrene NPs

240 nm

Penicillamine

Deliver D-penicillamine to the brain for the prevention of Aβ accumulation

Hadavi and Poot [32]

Sahni et al. [103]

Saraiva et al. [113]

Core–shell NPs

Thioflavin T and S

Tools to trace and clear Aβ in the brain

Sahni et al. [103]

Busquets et al. [110]

Sonmez et al. [120]

Nanolipidic and microparticles

30–80 nm

Polyphenol EGCG, donepezil

Prevent Aβ formation. Acetylcholine esterase inhibitor with high specificity for acetylcholine esterase in the central nervous system

Hadavi and Poot [32]

Sahni et al. [103]

Trimethylated chitosan conjugated-PLGA NPs

94 ± 8.1 to 146.5 ± 5.1

Coenzyme Q10(Co-Q10)

Q10-loaded TMC/PLGA–NP greatly improved memory impairment and restoring it to a normal level

Sahni et al. [103]

Poly(butyl) cyanoacrylate NPs

178 ± 0.59 to 197 ± 2.3

Apo-E binding

Attachment of ApoE3 to C-PBCA NPs increased the uptake of curcumin into cells as compared to the plain solution or untargeted NPs

Sahni et al. [103]

Nanoemulsions

10–1000 nm

Nano-PSO, lipid-coated microbubble/NP-derived (LCM/ND)-scavenger receptor class B type I

Good solubilization and protection of lipophilic drugs in the oil droplets and easy for large-scale production

Wen et al. [105]

Mizrahi et al. [121]

Microemulsions

1–100 nm

Huperzine A and ligustrazine phosphate

Microemulsions are optically isotropic and thermodynamically stable liquid solution and showed great improvements in the cerebral cholinergic function and oxidative systems that further slow down the progression of Alzheimer’s disease

Wen et al. [105]

Shi et al. [122]

Dendrimers

ADDL—amyloid-beta-derived diffusible ligands, (PPIG4-Mal) and fifth (PPI-G5-Mal) phosphorus-containing dendrimers

To modulate amyloidogenesis and stop the aggregation of Tau protein. Interfering with Aβ fibrilization in Alzheimer’s disease

Wen et al. [105]

Tomasz [123]

None of the non-steroidal-based drugs namely phenserine, statins, tarenflurbil, tramiprosate, and xaliproden have exhibited satisfactory efficiency in treatment of neurological disorders [124, 125, 126]. However, it is known that high levels of cholesterol are related with increased risk of AD. It has been verified based on animal studies that hypercholesterolemia promotes Aβ production and deposition. Currently, there are also two classes of medication approved for the AD treatment. The choline esterase inhibitor (ChEI) donepezil (Aricept), galantamine (Reminyl), and rivastigmine (Exelon) are prescribed for the treatment of mild to moderate AD. The N-methyl-D-aspartate antagonist memantine is the only medicine for the treatment of moderate to severe dementia. Excess ions of iron, zinc, and copper cause precipitation of Aβ leading to the development of toxic Aβ oligomers [127]. Formation of Aβ oligomers can be easily prevented if the above metal ions are chelated with non-toxic ligands such as diferrioximme or D-penicillamine, giving soluble complexes which can be removed from living system. Polystyrene NPs of 240 nm conjugated with deferiprone administrated to cultured human cortical neurons in vitro showed decreased cytotoxicity by preventing Aβ aggregation [128]. However, the bioavailability and toxicity limit their application in the human system. Nanocarriers facilitate this property by conjugation of chelating agent with them.

Likewise, 5-chloro-7-iodo-8-hydroxyquinoline (a quinol derivative) is known to have high affinity for zinc and copper ions. Treatment of AD transgenic mice with this quinol blocked Aβ aggregation [129]. Soluble complex formulation in low concentration prevents the interaction of metal with other ligating proteins. The efficiency and bioavailability of quinol can be increased by encapsulating with PBCA NPs coated with polysorbate 80. These quinol NPs were reported to cross the BBB in wild-type mice indicating potential for the AD treatment [129].

Naturally occurring molecules have also been suggested in AD treatment. For instance, curcumin from turmeric and quercetin flavonoid from fruits and vegetables are anti-inflammatory, antioxidant, and anti-cancer in nature. Liposomes of 170 nm prepared from curcumin–phospholipid conjugates have demonstrated to have high affinity with Aβ fibrils in vitro and very low affinity to Aβ monomers [130]. Liposomes work as a carrier to deliver therapeutic molecules in AD patients. Similarly, quercetin has also demonstrated to protect primary rat hippocampal neurons from Aβ cytotoxicity, protein oxidation, lipid peroxidation, and apoptosis [131]. Oral doses of quercetin in mouse showed improvement in learning and memory capability but its absorption in intestine is low and causing its rapid elimination [132]. When liposome-encapsulated quercetin was nasally administered, it inhibited the degeneration of hippocampal neurons in rat model of AD [133]. The confirmation of the protein in AD plays a significant role. The peptide may adopt a β-sheet confirmation or coil formation. An appreciable decrease in insoluble and soluble Aβ peptide in mice brain has been observed. However, conformational change is significant in the treatment of AD. The gold NPs are frequently used in the treatment of AD under electromagnetic field. As shown in Scheme 2 below; the NPs loaded with drug are photothermally excised and absorb the light energy which is converted to thermal energy and increases the temperature of the NP which destroys the target cells without damaging the normal healthy cells.
Scheme 2

Role of gold nanoparticles in Alzheimer's disease treatment

Parkinson’s Disease

PD is a neurodegenerative disease that annually affects one individual in every 100 persons aged above 65 years. This disease causes severe complications in patient body motions by affecting neuro-inflammatory responses. The use of nanotechnology could be a powerful tool to alleviate PD. Engineered NMs can promote regeneration and protection of affected neurons and also enhance the drug and small molecule delivery across the BBB. To overcome the side effects of conventional therapy for PD, extensive research is currently being conducted on the development of many strategies and techniques like nano-enabled scaffold device for biometric simulation and optimization and direct and targeted delivery into the brain. Currently, peptides and peptide NPs are being used not only in PD but also in other CNS disease diagnosis and treatment. But further development with improved and effective performance is urgently needed for delivery of nanomedicines into the CNS and brain tissue [46]. Gold- and TiO2-incorporated nanotube arrays recognize a-syn using photoelectrochemical immune sensors [134]. AFM studies in tandem with nanoneurotechnology can recognize protein misfolding of single a-syn molecules. Neuroinflammation and neurodegeneration inside neurons is effectively reduced by using catalase-packaged polyethyleneimine NPs. Additionally, anti-α-syn-conjugated polybutylcyanoacrylate NPs helped in neuronal a-syn clearance [23, 135, 136].

Amyotrophic Lateral Sclerosis

It is a motor neuronal disease and causes the loss of neuromuscular control with fatal outcomes [137]. The degeneration of motor neuron occurs in both lower and upper neurons. Protein inclusions as well as superoxide dismutase 1 (SOD1) are predominantly detected in both neurons and axons. A SOD-coated gold NP combined with SOD1 aggregates can be used as colorimetric detection system for ALS diagnosis [138]. The neuroprotective pathology can be achieved by using carboxyfullerene nanotubes with SOD [139]. The effective and accurate delivery of riluzole, a glutamate inhibitor to the effected sites, can be performed by using carbon NPs [140, 141].

Multiple Sclerosis

MS is an often disabling CNS disease. The most common symptom is disruption of information flow to the brain and in between the brain and body. The disease progression and myeloid neuronal infiltration can be achieved by using a water-soluble fullerene unified with an N-methyl-D-aspartate receptor antagonist in diseased patients tested poly (methyl methacrylate) and poly (caprolactone)-PEG (PCL-PEG) NPs. The therapeutic effect of the drug was increased in mice [142, 143, 144]. In another study, the co-polymers of PEG were used to load cells with catalase and finally it was delivered intravenously and the therapeutic activity was observed to increase in the inflamed brains [145]. Additionally, the disease severity was reduced by using poly (ethyleneimine) loaded with a therapeutic DNA in mice [58, 146].

Neurological Tumors

The treatment of neurological tumors (like brain tumors) has been investigated for many years by using polymeric NPs [147]. For the treatment of most of the tumor, a passive targeting technology using smaller than 100-nm NPs has been used with enhanced permeability, penetration, and retention effect which resulted into better gathering of NPs around the tumor region [143, 144]. The risk of elimination of NP, targeting brain tumor from the blood, can be overcome by engineering the better surface with receptors like folate which facilitate the NP accumulation at their site of action [142, 143]. Cabral and Kataoka [144] have suggested that the use of polymeric NPs for brain tumor study has reached an advanced stage of pre-clinical phase. The BBB was disrupted in many brain tumors except micrometastases or infiltrative gliomas [148]. Paclitaxel-loaded PEGylated PLGA-based NP was designed to target brain gliomas, and it was observed that the life span of mice increased twofolds [58, 145].

Ischemic Stroke

Currently, at global level, ischemic stroke is considered as a third root cause of death. It produces structural brain damage. The targeted and effective delivery of drugs and therapeutic compounds in the brain can be achieved by using stereotactic surgery [146]. Ischemic stroke treatment using nanomedicine in the brain has been already demonstrated [149]. CNTs are found to be very useful in brain imaging to identify stroke location and diseased site as well as delivery of drugs/therapeutic molecules to the site of action. The drug delivery by using nanotechnology will be a valuable tool for ischemic stroke and other chronic neurological diseases. Single-walled carbon nanotubes (SWCNTs) functionalized with amine groups increased the neuron tolerance to ischemic injury [147]. Application of nanodrug delivery could be of great benefit in the future for neuroprotection success in chronic neurological diseases including ischemic stroke. Neurotherapy with the use of CNTs would be extremely useful in the treatment of various neurological pathologies including ischemic stroke. Neurotrophin plays a significant role in the development and function of neurons as well as neuroprotection in both CNS and peripheral nervous system, and their delivery into the brain can be performed by using CNTs. The neuronal injury can be protected and functional motor recovery will be enhanced by pre-treatment with amine, functionalized with SWCNTs [20, 150].

Metal Chelators and NMs/NPs Used in Neurological Disease Management

Metal Chelators

Metal chelators or multidentate organic molecules form complexes with metal and are more stable than those formed with monodentate ligands. If these complexes are soluble in aqueous medium, they can easily be removed from the biological system and prevent toxicity. There are several such molecules such as desferrioxamine, an iron chelator, but it has also been used in the depletion of zinc, copper, and aluminum [151] in AD patients. Penicillamine is specifically used for the removal of copper from the brain. Although many transition metals are essential to human subjects in trace amounts, they become toxic when they exceed the tolerance limit and are involved in neuronal damage in neurological diseases. For instance, enhanced quantity of copper (390 μM), zinc (1055 μM), and iron (940 μM) has been observed to be present in AD brain in comparison to the normal adult samples (copper 70 μM, zinc 350 μM, and iron 340 μM) [63, 152, 153].

Nanomaterials

Currently, NMs are being frequently used in tissue engineering and targeted drug delivery. They play a significant role to overcome major problems related to effective and targeted drug delivery into the brain for diagnosis and treatment of neurological disorders [154, 155]. BBB allows free diffusion and transport of lipophilic molecules, oxygen, and carbon dioxide, and transporters or receptor-mediated endocytosis help the entry of other compounds in the brain [48]. Thus, to overcome these barriers and improve the effective delivery of therapeutic compounds in the brain, now, multiple tactics are being used viz. nanocarriers and strong conjugation of valuable drug compounds to the vectors having active transport capacity of drugs through BBB in the brain. Several NMs are produced using nanotechnology that can deliver desirable therapeutic compounds into the brain tissues as well as near the site of drug action in other tissues [32, 50, 51, 156]. Biodegradable materials as a carrier also revealed an effective drug delivery near the site of action. Thus, these preparation and treatments are likely to protect, repair, and regulate the damage of CNS tissues [51]. In addition, many NMs and polymers are extensively being used in the drug delivery system by coating with surfactant polysorbate 80 enabling them to easily cross BBB through receptor-mediated endocytosis. These polymers are known as polylactic acid, polyglycolic acid, polylactic-co-glycolic acid, polycaprolactone, chitosan, gelatin, and polybutyl cyanoacrylate [39, 154]. These NMs have additional properties as their surface can be manipulated and or engineered with hydrophilic polyethylene glycol layer allowing to protect the drugs from enzymatic degradation and recognition by the immune system [157]. Thus, these significant features enable those compounds to be considered as promising vehicle for AD and other neurological disease diagnosis and treatment [32].

Polymeric Nanoparticles

Polymeric NPs are solid colloidal particles containing macromolecular materials to attach, adsorb, dissolve, and encapsulate the drugs or therapeutic compounds. Degradable polymeric NPs of 10–100 nm are a common type of drug delivery systems for the neurological disease treatments. These particles exist in two variable units, nanocapsules and nanospheres [58, 148, 158, 159, 160]. Nanocapsules are made of coreshell NPs, whereas nanospheres contain homogeneous matrices. These particles sizes facilitate fine tuning to acquire desired properties like active compound protection with easy delivery and permeability of drugs into the target cells with higher efficacy and efficiency at low cost preparation [161, 162, 163]. Moreover, these particles are effective due to suitable degradation rate and their capability to cross BBB and reach the CNS [154]. Coating of suitable polymer with surfactant polysorbate 80 enables them to cross the BBB by adsorption of apolipoprotein E from the blood which is taken up by the cells of BBB by endocytosis [154]. Some modification in the characteristic preparation of NP coated with polymers may occur which protects the drug against immune system/enzymatic degradation [157]. Different signaling pathways are activated when interaction of growth factors (GFs) with their receptors on cell surface occurs. All pathways are different from each other. From animal studies, it has been observed that insulin-like growth factor (IGF), basic fibroblast growth factor (bFGF), and nerve growth factor (NGF) available in the brain exhibit useful influences [155]. It is, however, difficult to deliver GFs due to BBB, enzymatic degradation, clearance, and denaturation in the brain and the blood [164]. Kurakhmaeva et al. [165] revealed from animal studies that NGF-loaded poly (butyl cyanoacrylate) (PBCA) coated with polysorbate 80 improved memory function in mouse model. Intravenous administration of drug is an alternative route of transportation to the brain. It is expected that the drugs/therapeutic molecules are taken up by the olfactory epithelium and transported to the cerebrospinal fluid by passing the BBB [166]. Polymer NP of 120 nm loaded with the bFGF coated with Solanum tuberosum lectin has been shown to improve learning and memory capability in rat model of AD [167]. In addition, many polymeric NPs have been designed to treat brain tumors and neurodegenerative disorders [58]. They may be encapsulated as therapeutic agent and transported into the brain if it crosses the BBB.

Solid Lipid Nanoparticles

SLNs are also being used as efficient and alternative carriers for drug delivery as they have better advantages with improved characteristics. SLNs are known as an attractive colloidal drug carrier system for brain targeting. The accumulation of SLNs in reticulo endothelial system limits their use for targeted drug delivery in the brain. The lipid matrix is solid at room temperature with unique size and their better advantages to use as nanocarriers which allows better release and stability of drugs without causing cytotoxic effects in the tissue [41]. The SLNs have better advantages of reproducibility by using multiple strategies and larger scale-up feasibility. It is also a good option for other formulations that lack organic solvents. This also reduces the chance of residual contaminations. Based on these characters, SLN provides one of the most promising systems for drug delivery against many neurodegenerative disease and cancer treatment [40, 168, 169]. The drug stability into the blood and their entry through BBB can be enhanced by using NMs with SLN formulations as the polysorbate triggers the serum proteins by acting as anchor for apolipoproteins. The NPs coated with polysorbate provided desirable results for effective delivery of drugs across the BBB. The interaction of lipoproteins with capillary endothelial cell receptors available in brain with apolipoproteins facilitates the crossing of BBB. The phagocytosis can also be prevented by surface modification of SLN by coating with hydrophilic polymers or surfactants [170]. Furthermore, the use of ligands to SLN surface also improves the drug concentration and increased drug stability and availability across BBB for the neurological treatments. However, to date, only few drugs are FDA-approved for AD, known as acetylcholinesterase inhibitors (donepezil, galantamine, and rivastigmine). Nonetheless, recently, solid NPs having galantamine hydrobromide have been developed to upgrade the drug bioavailability for AD treatment [40, 171].

Liposomes

Liposomes are spherical vesicles made of impermeable lipid bilayer, phospholipids, and cholesterol. They are being considered as an important vehicle for drug delivery due to their non-toxic and biocompatibility characteristics. They can deliver hydrophilic and hydrophobic molecules by carrying the aqueous and lipid parts of the liposomes. Though, they are recognized as foreign particles by the biological system without causing any negative response after their entry into the system, they are non-immunogenic as well as non-carcinogenic, biodegradable, and non-thrombogenic in nature [172]. Liposomes are being used as larger transport nanocarriers as they are capable of encapsulating multiple components. Additionally, they are protected against enzymatic degradation and removal by the reticuloendothelial system. The most important characteristics are capability to fuse with biological membranes, move across cell membrane, and to penetrate the BBB. The half-life of liposome can be easily enhanced by treating their surface with PEG [173]. The Aβ oligomers with high affinity towards liposomes can be used for delivery of therapeutic compounds in animal models [174]. In an in vitro study, using phosphatidylcholine liposomes having omega-3 fatty acid and docosahexaenoic acid into APP-overexpressing cells, it was observed that the cell membrane fluidity increased. The induction of non-amyloidogenic processing of APP resulted into formation of soluble APPα (sAPPα) and further the inhibition of JNK stress signaling pathway by sAPPα-containing cell supernatants; PI3K/Akt survival pathway was activated in cultured neuronal cells and finally resulted into prevention of apoptotic cell death [175]. So, liposomes containing DHA could be used for prevention and treatment of AD [32].

Gold Nanoparticles

Gold NPs are being effectively utilized for drug delivery against various diseases [17]. They have many important characteristics such as better biocompatibility, easy synthesis, and simplistic surface functionalization with easy and effective delivery to target cells and tissues [17, 18]. Some reports have shown that the gold NPs can be utilized in AD disease treatment by destructing and dissolving the Aβ fibrils and plaques with the help of weak microwave field exposure in the brain tissue. Major cases of AD are plaque formation and Aβ fibrils in the brain which can be either prevented or destroyed. Gold NP interaction with fibrils followed by their exposure to weak microwaves causes an increase in the temperature and dissolution of fibrils. Experiment in mice (in vitro) has shown that gold NPs slow down the progression of AD. It is also interesting to note that apparently NPs do not adversely affect the brain [176]. Gold NPs conjugated with some compounds interfering with Aβ fibrils have been used [114, 115]. Gao et al. [115] have reported that the gold NPs of 22-nm size reduces the cytotoxicity of Aβ fibrils and Aβ-mediated peroxidase activity in vitro. Triulzi et al. [177] have demonstrated the photochemical ablation of Aβ plaques in AD. They have suggested that gold NPs formed complexes with synthesized β-amyloid peptides. Upon irradiation with laser beam, the complex containing NP was stabilized. Gold NP conjugated with ematoporphyrin has been reported to be effective against T cell lines MT-4 and Jurkat cells (human T cell leukemia) [178] in vitro. They have been used as probe to detect neuronal cell activity [148]. Gold NP suspension of drug from nanobubbles can deliver the drug to the target site when the bubble bursts by heating. Based on these results, the use of gold NPs is a better option in AD disease diagnosis, treatment, and management [32, 115]. Overall, the metal NPs have shown a considerable potential in the treatment of neurological diseases.

Microparticles

MPs are basically a heterogenous population of small cell-derived (0.1–1 μm) vesicles and are now being used as an important vehicle for drug delivery and AD treatment. In the CNS, these particles have been detected in the CSF, where they are discharged by almost all types of cells [179, 180]. It is well known that the FDA-approved donepezil drug is being used in the improvement of daily life functioning and cognition of mild-to-moderate AD patients without causing any damage and significant changes in the function of vital organs till > 98 weeks. This medicine is being used as a daily dose but it causes gastrointestinal side effects as well as impaired memory. Nonetheless, this problem could be solved now by using PLGA donepezil-loaded microparticles for long-term use [181]. These particles were implanted subcutaneously in rats which resulted in steady-state plasma levels of donepezil for 4 weeks, and then, this drug was rapidly reduced. In another study, microparticles were used on rat after ligating with common carotid arteries and neuronal loss with reduced learning and memory capabilities was reported. The above result indicates that the use of FDA-approved drugs can be more beneficial with control release strategies for the treatment of AD [32, 182].

Carbon Nanotubes and Fullerenes

The carbon nanotube (CNT) was discovered in 1991 by Iijima [183]. They have many valuable properties such as ultra-light weight, high flexibility, low deposition, low cost, high capability, ultra-strong, and inert with electrical and thermal conductivity. Currently, it has emerged as new promising NMs due to useful and exclusive properties for treatment of neurological disorders viz. in AD, PD, and ischemic stroke [20, 184, 185]. The successful utilization of CNTs as drug delivery vehicles in vivo has been reported in many diseases like bone implants, rheumatoid arthritis, osteoporosis, and cancer [184, 186]. However, very limited preclinical studies have been performed for successful application of CNTs in neurological disorders [187]. Fullerene derivatives have also been investigated for their role as neuroprotective agents [188]. For instance, nanostructures of hydrated C60 fullerene (C60HyFn) showed protection on the CNS in rats against chronic alcoholization [189]. Authors have suggested an indirect participation of C60HyFn in the neurotransmitter metabolism. In addition, some reports have also shown that the fullerene derivatives contain multiple synergistic mechanisms that can be employed for AD treatment [190].

Conclusions

All neurological disorders are associated with the spinal cord and nervous system. AD leads to the cognitive impairment and plaque deposits in the brain leading to neuronal cell death. Hence, it has been suggested to prevent the loss of functional neurons or to replace the damaged neurons. BBB provides protection to the brain, so an important challenge for any drug is to cross the BBB and to reach the CNS with desirable amount. It is therefore crucial to develop a benign and effective drug delivery system with improved efficacy which may effectively cross the BBB and reach the target cells without producing any significant adverse effects. Different NMs and/or NPs have been developed, utilized, and tested and showed promising contribution in the diagnosis, treatment, and management of neurological disorders. Drug-loaded NPs are tested for AD treatment and provided promising results. In addition, the significance of NMs in stem cell therapy for several kinds of neurological diseases is elucidated. NMs are also able to promote stem cell proliferation and differentiation and also contribute dominant roles in stem cell imaging and tracking. Thus, in CNS-related diseases, the use of NMs/NPs in drug delivery is a better option in comparison to the conventional mode of treatments. However, their systematic toxicity investigations are also required for the effective formulation and application in neurological disorders.

Notes

Authors’ Contributions

AH and SSS gathered the research data. AH, SS, KSS, and MSY analyzed these data and wrote this review paper. All the authors read and approved the final manuscript.

Ethics Approval and Consent to Participate

Not applicable

Consent for Publication

Not applicable

Competing Interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Huang L, Hu J, Huang S, Wang B, Siaw-Debrah F, Nyanzu M, Zhang Y, Zhuge Q (2017) Nanomaterial applications for neurological diseases and central nervous system injury. Prog Neurobiol 157:29–48CrossRefGoogle Scholar
  2. 2.
    Husen A, Siddiqi KS (2014a) Carbon and fullerene nanomaterials in plant system. J Nanobiotechnol 12:16CrossRefGoogle Scholar
  3. 3.
    Husen A, Siddiqi KS (2014b) Phytosynthesis of nanoparticles: concept, controversy and application. Nano Res Lett 9:229CrossRefGoogle Scholar
  4. 4.
    Husen A, Siddiqi KS (2014c) Plants and microbes assisted selenium nanoparticles: characterization and application. J Nanobiotechnol 12:28CrossRefGoogle Scholar
  5. 5.
    Sadegh H, Shahryari-ghoshekandi R (2015) Functionalization of carbon nanotubes and its application in nanomedicine: a review. Nanomed J 2:231–248Google Scholar
  6. 6.
    Siddiqi KS, Rahman A, Tajuddin, Husen A (2018) Properties of zinc oxide nanoparticles and their activity against microbes. Nano Res Lett 13:141CrossRefGoogle Scholar
  7. 7.
    Siddiqi KS, Husen A (2016a) Fabrication of metal nanoparticles from fungi and metal salts: scope and application. Nano Res Lett 11:98CrossRefGoogle Scholar
  8. 8.
    Siddiqi KS, Husen A (2016b) Fabrication of metal and metal oxide nanoparticles by algae and their toxic effects. Nano Res Lett 11:363CrossRefGoogle Scholar
  9. 9.
    Siddiqi KS, Husen A (2016c) Engineered gold nanoparticles and plant adaptation potential. Nano Res Lett 11:400CrossRefGoogle Scholar
  10. 10.
    Siddiqi KS, Husen A (2016d) Green synthesis, characterization and uses of palladium/platinum nanoparticles. Nano Res Lett 11:482CrossRefGoogle Scholar
  11. 11.
    Siddiqi KS, Rahman A, Tajuddin, Husen A (2016) Biogenic fabrication of iron/iron oxide nanoparticles and their application. Nano Res Lett 11:498CrossRefGoogle Scholar
  12. 12.
    Siddiqi KS, Husen A (2017a) Plant response to engineered metal oxide nanoparticles. Nano Res Lett 12:92CrossRefGoogle Scholar
  13. 13.
    Keller AA, Lazareva A (2013) Predicted releases of engineered nanomaterials: from global to regional to local. Environ. Sci Technol Lett 1:65–70Google Scholar
  14. 14.
    Weir A, Westerhoff P, Fabricius L, Hristovski K, von Goetz N (2012) Titanium dioxide nanoparticles in food and personal care products. Environ Sci Technol 46:2242–2250CrossRefGoogle Scholar
  15. 15.
    Sharma VK, Yngard RA, Lin Y (2009) Silver nanoparticles: green synthesis and their antimicrobial activities. Adv Colloid Interf Sci 145:83–96CrossRefGoogle Scholar
  16. 16.
    Lara HH, Garza-Treviño EH, Ixtepan-Turrent L, Singh DK (2011) Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds. J Nanobiotechnol 9:30CrossRefGoogle Scholar
  17. 17.
    Siddiqi KS, Husen A (2017b) Recent advances in plant-mediated engineered gold nanoparticles and their application in biological system. J Trace Elements Med Biol 40:10–23CrossRefGoogle Scholar
  18. 18.
    Husen A (2017) Gold nanoparticles from plant system: synthesis, characterization and application. In: Nanoscience and Plant–Soil SystemsVol. 48 (Eds. Ghorbanpourn M, Manika K, Varma A) Springer International Publishing AG, Gewerbestrasse 11, 6330 Cham, Switzerland, pp.455–479Google Scholar
  19. 19.
    Kora AJ, Rastogi L (2015) Green synthesis of palladium nanoparticles using gum ghatti (Anogeissus latifolia) and its application as an antioxidant and catalyst. Arab J Chem  https://doi.org/10.1016/j.arabjc.2015.06.024
  20. 20.
    Komane PP, Choonara YE, du Toit LC, Kumar P, Kondiah PDP, Modi G, Pillay V (2016) Diagnosis and treatment of neurological and ischemic disorders employing carbon nanotube technology. J Nanomat 9417874:19Google Scholar
  21. 21.
    Wong HL, Wu XY, Bendayan R (2012) Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 64:686–700CrossRefGoogle Scholar
  22. 22.
    Fonseca-Santos B, Gremião MPD, Chorilli M (2015) Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease. Int J Nanomedicine 10:4981–5003CrossRefGoogle Scholar
  23. 23.
    Paurush A, Daniel GA (2015) Nanotechnology in neurology: genesis, current status, and future prospects. Ann Ind Acad Neurol 18:382–386Google Scholar
  24. 24.
    Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ (1992) Mutation of the beta-amyloid precursor protein in familial Alzheimer’s disease increases beta-protein production. Nature 360:672–674CrossRefGoogle Scholar
  25. 25.
    Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, Da Silva HA, Haines JL, Perkicak-Vance MA, Tanzi RE, Roses AD, Fraser PE, Rommens JM, St George-Hyslop PH (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 375:754–760CrossRefGoogle Scholar
  26. 26.
    Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, Mar L, Sorbi S, Nacmias B, Piacentini S, Amaducci L, Chumakov I, Cohen D, Lannfelt L, Fraser PE, Rommens JM, St George-Hyslop PH (1995) Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature 376:775–778CrossRefGoogle Scholar
  27. 27.
    Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112–2117CrossRefGoogle Scholar
  28. 28.
    Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S (1993) Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet 342:697–699CrossRefGoogle Scholar
  29. 29.
    Barabash A, Marcos A, Ancin I, Vazquez-Alvarez B, de Ugarte C, Gil P, Fernandez C, Encinas M, Lopez-Ibor JJ, Cabranes JA (2009) APOE, ACT and CHRNA7 genes in the conversion from amnestic mild cognitive impairment to Alzheimer’s disease. Neurobiol Aging 30:1254–1264CrossRefGoogle Scholar
  30. 30.
    Modi G, Pillay V, Choonara YE, Ndesendo VM, du Toit LC, Naidoo D (2009) Nanotechnological applications for the treatment of neurodegenerative disorders. Prog Neurobiol 88:272–285CrossRefGoogle Scholar
  31. 31.
    Anand R, Gill KD, Mahdi AA (2014) Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology 76:27–50CrossRefGoogle Scholar
  32. 32.
    Hadavi D, Poot AA (2016) Biomaterials for the treatment of Alzheimer’s disease. Front Bioeng Biotechnol 4:49CrossRefGoogle Scholar
  33. 33.
    Yokel R, Grulke E, Macphail R (2013) Metal-based nanoparticle interactions with the nervous system: the challenge of brain entry and the risk of retention in the organism. Wiley Interdiscip Rev Nanomed Nanobiotechnol 5:346–373CrossRefGoogle Scholar
  34. 34.
    Bachler G, Von Goetz N, Hungerbuhler K (2015) Using physiologically based pharmacokinetic (PBPK) modeling for dietary risk assessment of titanium dioxide (TiO2) nanoparticles. Nanotoxicology 9:373–380CrossRefGoogle Scholar
  35. 35.
    Hu Q, Guo F, Zhao F, Fu Z (2017) Effects of titanium dioxide nanoparticles exposure on parkinsonism in zebrafish larvae and PC12. Chemosphere 173:373–379CrossRefGoogle Scholar
  36. 36.
    Yoo J, Lee E, Kim HY, Youn DH, Jung J, Kim H, Chang Y, Lee W, Shin J, Baek S, Jang W, Jun W, Kim S, Hong J, Park HJ, Lengner CJ, Moh SH, Kwon Y, Kim J (2017) Electromagnetized gold nanoparticles mediate direct lineage reprogramming into induced dopamine neurons in vivo for Parkinson’s disease therapy. Nat Nanotech 12:1006–1014CrossRefGoogle Scholar
  37. 37.
    Re F, Gregori M, Masserini M (2012) Nanotechnology for neurodegenerative disorders. Nanomed Nanotechnol Biol Med 8:S51–S58CrossRefGoogle Scholar
  38. 38.
    Kanwar JR, Sriramoju B, Kanwar RK (2012) Neurological disorders and therapeutics targeted to surmount the blood–brain barrier. Int J Nanomedicine 7:3259–3278CrossRefGoogle Scholar
  39. 39.
    Sulheim E, Baghirov H, von Haartman E, Bøe A, Åslund AK, Mørch Y, Davies Cde L (2016) Cellular uptake and intracellular degradation of poly(alkyl cyanoacrylate) nanoparticles. J Nanobiotechnol 14:1CrossRefGoogle Scholar
  40. 40.
    Cacciatore I, Ciulla M, Fornasari E, Marinelli L, Di Stefano A (2016) Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases. Expert Opin Drug Deliv 13:1121–1131CrossRefGoogle Scholar
  41. 41.
    Roney C, Kulkarni P, Arora V, Antich P, Bonte F, Wu A, Mallikarjuana NN, Manohar S, Liang HF, Kulkarni AR, Sung HW, Sairam M, Aminabhavi TM (2005) Targeted nanoparticles for delivery through blood brain barrier for Alzheimer’s disease. J Cont Rel 108:193–214CrossRefGoogle Scholar
  42. 42.
    Vashist A, Kaushik A, Vashist A, Bala J, Nikkhah-Moshaie R, Sagar V, Nair M (2018) Nanogels potential drug nanocarriers for CNS drug delivery. Drug Discov Today  https://doi.org/10.1016/j.drudis.2018.05.018
  43. 43.
    Zhang W, Wang GM, Wang PJ, Zhang Q, Sha SH (2014b) Effects of neural stem cells on synaptic proteins and memory in a mouse model of Alzheimer’s disease. J Neurosci Res 92:185–194CrossRefGoogle Scholar
  44. 44.
    Zhang G, Khan AA, Wu H, Chen L, Gu Y, Gu N (2017) The application of nanomaterials in stem cell therapy for some neurological diseases. Curr Drug Targets.  https://doi.org/10.2174/1389450118666170328115801
  45. 45.
    Trekker J, Himmelreich U, Beiras A, Topete A, Taboada P, Pérez-Mato M, Vieites-Prado A, Iglesias-Rey R, Rivas J, Planas AM, Sobrino T, Castillo J, Campos F (2017) Intraarterial route increases the risk of cerebral lesions after mesenchymal cell administration in animal model of ischemia. Sci Rep 7:40758CrossRefGoogle Scholar
  46. 46.
    Anna PN (2015) Nanotechnology and its applications in medicine. Med Chem 5:2Google Scholar
  47. 47.
    Sun L, Liu SY, Zhou XW, Wang XC, Liu R, Wang Q, Wang JZ (2003) Inhibition of protein phosphatase 2A- and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats. Neuroscience 118:1175–1182CrossRefGoogle Scholar
  48. 48.
    Ballabh P, Braun A, Nedergaard M (2004) The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 16:1–13CrossRefGoogle Scholar
  49. 49.
    Lockman PR, Oyewumi MO, Koziara JM, Roder KE, Mumper RJ, Allen DD (2003) Brain uptake of thiamine-coated nanoparticles. J Control Release 93:271–282CrossRefGoogle Scholar
  50. 50.
    Beduneau A, Saulnier P, Benoit JP (2007) Active targeting of brain tumors using nanocarriers. Biomaterials 28:4947–4967CrossRefGoogle Scholar
  51. 51.
    Orive G, Anitua E, Pedraz JL, Emerich DF (2009) Biomaterials for promoting brain protection, repair and regeneration. Nat Rev Neurosci 10:682–692CrossRefGoogle Scholar
  52. 52.
    Ritchie CW, Bush AI, Masters CL (2004) Metal-protein attenuating compounds and Alzheimer’s disease. Expert Opin Invest Drug 13:1585–1592CrossRefGoogle Scholar
  53. 53.
    Hartig W, Paulke B, Varga C, Seeger J, Harkany T, Kacza J (2003) Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting h-amyloid in Alzheimer’s disease. Neurosci Lett 338:174–176CrossRefGoogle Scholar
  54. 54.
    Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2:1403CrossRefGoogle Scholar
  55. 55.
    Francis PT, Palmer AM, Snape M, Wilcock GK (1999) The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 66:137–147CrossRefGoogle Scholar
  56. 56.
    Fontana DJ, Inouye GT, Johnson RM (1994) Linopirdine (DuP 996) improves performance in several tests of learning and memory by modulation of cholinergic neuro transmission. Pharmacol Biochem Behav 49:1075–1082CrossRefGoogle Scholar
  57. 57.
    Kurihara K, Ueda M, Hara I, Ozeki E, Togashi K, Kimura S (2018) Polymeric micelle of A B-type lactosome as a vehicle for targeting meningeal dissemination. Nanomaterials 8:79Google Scholar
  58. 58.
    Fornaguera C, Solans C (2016) Polymeric nanoparticles for drug delivery in neurological diseases. Curr Pathobiol Rep 4:189–197CrossRefGoogle Scholar
  59. 59.
    Barbu E, Molnàr E, Tsibouklis J, Górecki DC (2009) The potential for nanoparticle-based drug delivery to the brain: overcoming the blood–brain barrier. Expert Opin Drug Deliv 6:553–565CrossRefGoogle Scholar
  60. 60.
    Yang ZZ, Zhang YQ, Wang ZZ, Wu K, Lou JN, Qi XR (2013) Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int J Pharm 452:344–354CrossRefGoogle Scholar
  61. 61.
    Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B (2008) Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 70:75–84CrossRefGoogle Scholar
  62. 62.
    Zhang C, Wan X, Zheng X, Shao X, Liu Q, Zhang Q, Qian Y (2014) Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer’s disease mice. Biomaterials 35:456–465CrossRefGoogle Scholar
  63. 63.
    Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998) Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci 158:47–52CrossRefGoogle Scholar
  64. 64.
    Castellani RJ, Smith MA, Nunomura A, Harris PL, Perry G (1999) Is increased redoxactive iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? Free Radic Biol Med 26:1508–1512CrossRefGoogle Scholar
  65. 65.
    Lee JY, Mook-Jung I, Koh JY (1999) Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice. J Neurosci 19:RC10CrossRefGoogle Scholar
  66. 66.
    Opazo C, Huang X, Cherny RA, Moir RD, Roher AE, White AR, Cappai R, Masters CL, Tanzi RE, Inestrosa NC, Bush AI (2002) Metalloenzyme-like activity of Alzheimer’s disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem 277:40302–40308CrossRefGoogle Scholar
  67. 67.
    Ali FE, Separovic F, Barrow CJ, Cherny RA, Fraser F, Bush AI, Masters CL, Barnham KJ (2005) Methionine regulates copper/hydrogen peroxide oxidation products of Abeta. J Pept Sci 11:353–360CrossRefGoogle Scholar
  68. 68.
    Barnham KJ, Haeffner F, Ciccotosto GD, Curtain CC, Tew D, Mavros C, Beyreuther K, Carrington D, Masters CL, Cherny RA, Cappai R, Bush AI (2004) Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer’s disease beta-amyloid. FASEB J 18:1427–1429CrossRefGoogle Scholar
  69. 69.
    Singh M, Arseneault M, Sanderson T, Murthy V, Ramassamy C (2008) Challenges for research on polyphenols from foods in Alzheimer’s disease: bioavailability, metabolism, and cellular and molecular mechanisms. J Agric Food Chem 56:4855–4873CrossRefGoogle Scholar
  70. 70.
    Choi YT, Jung CH, Lee SR, Bae JH, Baek WK, Suh MH, Park J, Park CW, Suh SI (2001) The green tea polyphenol (−)-epigallocatechin gallate attenuates betaamyloid-induced neurotoxicity in cultured hippocampal neurons. Life Sci 70:603–614CrossRefGoogle Scholar
  71. 71.
    Levites Y, Amit T, Mandel S, Youdim MB (2003) Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (−)-epigallocatechin-3-gallate. FASEB J 17:952–954CrossRefGoogle Scholar
  72. 72.
    Bastianetto S, Yao ZX, Papadopoulos V, Quirion R (2006) Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloid induced toxicity. Eur J Neurosci 23:55–64CrossRefGoogle Scholar
  73. 73.
    Ladiwala AR, Lin JC, Bale SS, Marcelino-Cruz AM, Bhattacharya M, Dordick JS, Tessier PM (2010) Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers. J Biol Chem 285:24228–24237CrossRefGoogle Scholar
  74. 74.
    Marambaud P, Zhao H, Davies P (2005) Resveratrol promotes clearance of Alzheimer’s disease amyloid-beta peptides. J Biol Chem 280:37377–37382CrossRefGoogle Scholar
  75. 75.
    Han YS, Zheng WH, Bastianetto S, Chabot JG, Quirion R (2004) Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br J Pharmacol 141:997–1005CrossRefGoogle Scholar
  76. 76.
    Haque AM, Hashimoto M, Katakura M, Hara Y, Shido O (2008) Green tea catechins prevent cognitive deficits caused by Abeta1–40 in rats. J Nutr Biochem 19:619–626CrossRefGoogle Scholar
  77. 77.
    Kumar A, Naidu PS, Seghal N, Padi SSV (2007) Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats. Pharmacology 79:17–26CrossRefGoogle Scholar
  78. 78.
    Regitz C, Fitzenberger E, Mahn FL, Dußling LM, Wenzel U (2016) Resveratrol reduces amyloid-beta (Aβ1–42)-induced paralysis through targeting proteostasis in an Alzheimer model of Caenorhabditis elegans. Eur J Nutr 55:741–747CrossRefGoogle Scholar
  79. 79.
    Wang H, Jiang T, Li W, Gao N, Zhang T (2018) Resveratrol attenuates oxidative damage through activating mitophagy in an in vitro model of Alzheimer’s disease. Toxicol Lett 282:100–108CrossRefGoogle Scholar
  80. 80.
    Yin H, Wang H, Zhang H, Gao N, Zhang T, Yang Z (2017) Resveratrol attenuates Aβ-induced early hippocampal neuron excitability impairment via recovery of function of potassium channels. Neurotox Res 32:311–324CrossRefGoogle Scholar
  81. 81.
    Liu H, Li Z, Qiu D, Gu Q, Lei Q, Mao L (2010) The inhibitory effects of different curcuminoids on beta-amyloid protein, beta-amyloid precursor protein and beta-site amyloid precursor protein cleaving enzyme 1 in swAPP HEK293 cells. Neurosci Lett 485:83–88CrossRefGoogle Scholar
  82. 82.
    Ono K, Hasegawa K, Naiki H, Yamada M (2004) Curcumin has potent antiamyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. J Neurosci Res 75:742–750CrossRefGoogle Scholar
  83. 83.
    Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280:5892–5901CrossRefGoogle Scholar
  84. 84.
    Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ (2007) Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102:1095–1104CrossRefGoogle Scholar
  85. 85.
    Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21:8370–8377CrossRefGoogle Scholar
  86. 86.
    Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, Cole GM (2001) Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology, Neurobiol. Aging 22:993–1005Google Scholar
  87. 87.
    Kim DS, Park SY, Kim JK (2001) Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1–42) insult. Neurosci Lett 303:57–61CrossRefGoogle Scholar
  88. 88.
    Ishrat T, Hoda MN, Khan MB, Yousuf S, Ahmad M, Khan MM, Ahmad A, Islam F (2009) Amelioration of cognitive deficits and neurodegeneration by curcumin in rat model of sporadic dementia of Alzheimer’s type (SDAT). Eur Neuropsychopharmacol 19:636–647CrossRefGoogle Scholar
  89. 89.
    Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, Hardy J, Town T, Tan J (2005) Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25:8807–8814CrossRefGoogle Scholar
  90. 90.
    Jeon SY, Bae KH, Seong YH, Song KS (2003) Green tea catechins as a BACE1 (betasecretase) inhibitor. Bioorg Med Chem Lett 13:3905–3908CrossRefGoogle Scholar
  91. 91.
    Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15:558–566CrossRefGoogle Scholar
  92. 92.
    Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, Wanker EE (2010) EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci U S A 107:7710–7715CrossRefGoogle Scholar
  93. 93.
    Kim SJ, Jeong HJ, Lee KM, Myung NY, An NH, Yang WM, Park SK, Lee HJ, Hong SH, Kim HM, Um JY (2007) Epigallocatechin-3-gallate suppresses NF-kappaB activation and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells. J Nutr Biochem 18:587–596CrossRefGoogle Scholar
  94. 94.
    Baum L, Ng A (2004) Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer’s disease animal models. J Alzheimers Dis 6:367–3778 discussion 443–369CrossRefGoogle Scholar
  95. 95.
    Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharm 4:807–818CrossRefGoogle Scholar
  96. 96.
    Yang KY, Lin LC, Tseng TY, Wang SC, Tsai TH (2007) Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 853:183–189CrossRefGoogle Scholar
  97. 97.
    Ravindranath V, Chandrasekhara N (1981) Metabolism of curcumin—studies with [3H] curcumin. Toxicology 22:337–344CrossRefGoogle Scholar
  98. 98.
    Rapoport SI (1996) Modulation of blood-brain barrier permeability. J Drug Target 3:417–425CrossRefGoogle Scholar
  99. 99.
    Banks WA, Kastin AJ, Barrera CM (1991) Delivering peptides to the central nervous system: dilemmas and strategies. Pharm Res 8:1345–1350CrossRefGoogle Scholar
  100. 100.
    Sonavane G, Tomoda K, Makino K (2008) Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Coll Surf B Biointerf 66:274–280CrossRefGoogle Scholar
  101. 101.
    Huber JD, Egleton RD, Davis TP (2001) Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci 24:719–725CrossRefGoogle Scholar
  102. 102.
    Faraji AH, Wipf P (2009) Nanoparticles in cellular drug delivery. Bioorg Med Chem 17:2950–2962CrossRefGoogle Scholar
  103. 103.
    Sahni JK, Doggui S, Ali J, Baboota S, Dao L, Ramassamy C (2011) Neurotherapeutic applications of nanoparticles in Alzheimer’s disease. J Cont Rel 152:208–231CrossRefGoogle Scholar
  104. 104.
    Gregori M, Masserini M, Mancini S (2015) Nanomedicine for the treatment of Alzheimer’s disease. Nanomedicine (Lond) 10:1203–1218CrossRefGoogle Scholar
  105. 105.
    Wen MM, El-Salamouni NS, El-Refaie WM, Hazzah HA, Ali MM, Tosi G, Farid RM, Blanco-Prieto MJ, Billa N, Hanafy AS (2017) Nanotechnology-based drug delivery systems for Alzheimer’s disease management: technical, industrial, and clinical challenges. J Cont Rel 245:95–107CrossRefGoogle Scholar
  106. 106.
    Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S (2015) Advances and challenges of liposome assisted drug delivery. Front Pharmacol 6:286CrossRefGoogle Scholar
  107. 107.
    Qu J, Zhang L, Chen Z, Mao G, Gao Z, Lai X, Zhu X, Zhu J (2016) Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy? Drug Deliv 23:3408–3416CrossRefGoogle Scholar
  108. 108.
    D’Arrigo JS (2017) Alzheimer’s disease, brain injury, and C.N.S. nanotherapy in humans: sonoporation augmenting drug targeting. Med Sci 5:29Google Scholar
  109. 109.
    Ahmed TA, Aljaeid BM (2016) Preparation, characterization, and potential application of chitosan, chitosan derivatives, and chitosan metal nanoparticles in pharmaceutical drug delivery. Drug Des Devel Ther 10:483–507CrossRefGoogle Scholar
  110. 110.
    Busquets MA, Sabaté R, Estelrich J (2014) Potential applications of magnetic particles to detect and treat Alzheimer’s disease. Nano Res Lett 9:538CrossRefGoogle Scholar
  111. 111.
    Teller S, Tahirbegi IB, Mir M, Samitier J, Soriano J (2015) Magnetite-amyloid-β deteriorates activity and functional organization in an in vitro model for Alzheimer’s disease. Sci Rep 5:17261CrossRefGoogle Scholar
  112. 112.
    Chen YW, Chang CW, Hung HS, Kung ML, Yeh BW, Hsieh S (2016) Magnetite nanoparticle interactions with insulin amyloid fibrils. Nanotechnology 27:415702CrossRefGoogle Scholar
  113. 113.
    Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L (2016) Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases. J Cont Rel 235:34–47CrossRefGoogle Scholar
  114. 114.
    Karimi M, Bahrami S, Ravari SB, Zangabad PS, Mirshekari H, Bozorgomid M, Shahreza S, Sori M, Hamblin MR (2016) Albumin nanostructures as advanced drug delivery systems. Expert Opin Drug Deliv 13:1609–1623CrossRefGoogle Scholar
  115. 115.
    Gao N, Sun H, Dong K, Ren J, Qu X (2015) Gold-nanoparticle-based multifunctional amyloid-β inhibitor against Alzheimer’s disease. Chemistry 21:829–835CrossRefGoogle Scholar
  116. 116.
    Sarko DK, McKinney CE (2017) Exosomes: origins and therapeutic potential for neurodegenerative disease. Front Neurosci 11:82CrossRefGoogle Scholar
  117. 117.
    Quek C, Hill AF (2017) The role of extracellular vesicles in neurodegenerative diseases. Biochem Biophys Res Commun 483:1178–1186CrossRefGoogle Scholar
  118. 118.
    Chen JJ, Zhao B, Zhao J, Li S (2017) Potential roles of exosomal microRNAs as diagnostic biomarkers and therapeutic application in Alzheimer’s disease. Neural Plast 2017:7027380Google Scholar
  119. 119.
    Jiang XC, Gao JQ (2017) Exosomes as novel bio-carriers for gene and drug delivery. Int J Pharm 521:167–175CrossRefGoogle Scholar
  120. 120.
    Sonmez M, Georgescu M, Alexandrescu L, Gurau D, Ficai A, Ficai D, Andronescu E (2015) Synthesis and applications of Fe3O4/SiO2 core-shell materials. Curr Pharm Des 21:5324–5335CrossRefGoogle Scholar
  121. 121.
    Mizrahi M, Friedman-Levi Y, Larush L, Frid K, Binyamin O, Dori D, Fainstein N, Ovadia H, Ben-Hur T, Magdassi S, Gabizon R (2014) Pomegranate seed oil nanoemulsions for the prevention and treatment of neurodegenerative diseases: the case of genetic CJD. Nanomedicine 10:1353–1363CrossRefGoogle Scholar
  122. 122.
    Shi J, Cong W, Wang Y, Liu Q, Luo G (2012) Microemulsion-based patch for transdermal delivery of huperzine a and ligustrazine phosphate in treatment of Alzheimer’s disease. Drug Dev Ind Pharm 38:752–761CrossRefGoogle Scholar
  123. 123.
    Tomasz W, Marcinkowska M, Pieszynski I, Zablocka M, Caminade AM, Majora JP, Klajnert-Maculewiczae B (2015) Cationic phosphorus dendrimers and therapy for Alzheimer’s disease. New J Chem 39:4852CrossRefGoogle Scholar
  124. 124.
    Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Willson P, Kogan F (1993) Clinical trial of indomethacin in Alzheimer’s disease. Neurology 43:1609–1611CrossRefGoogle Scholar
  125. 125.
    Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N (1999) A double-blind, placebo controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology 53:197–201CrossRefGoogle Scholar
  126. 126.
    Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289:2819–2826CrossRefGoogle Scholar
  127. 127.
    Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, Bush AI (2008) Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59:43–55CrossRefGoogle Scholar
  128. 128.
    Liu G, Men P, Kudo W, Perry G, Smith MA (2009) Nanoparticle-chelator conjugates as inhibitors of amyloid-beta aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci Lett 455:187–190CrossRefGoogle Scholar
  129. 129.
    Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron 30:665–676CrossRefGoogle Scholar
  130. 130.
    Mourtas S, Canovi M, Zona C, Aurilia D, Niarakis A, La Ferla B, Salmona M, Nicotra F, Gobbi M, Antimisiaris SG (2011) Curcumin-decorated nanoliposomes with very high affinity for amyloid-beta1-42 peptide. Biomaterials 32:1635–1645CrossRefGoogle Scholar
  131. 131.
    Ansari MA, Abdul HM, Joshi G, Opii WO, Butterfield DA (2009) Protective effect of quercetin in primary neurons against Abeta(1-42): relevance to Alzheimer’s disease. J Nutr Biochem 20:269–275CrossRefGoogle Scholar
  132. 132.
    Lu J, Zheng YL, Luo L, Wu DM, Sun DX, Feng YJ (2006) Quercetin reverses d-galactose induced neurotoxicity in mouse brain. Behav Brain Res 171:251–260CrossRefGoogle Scholar
  133. 133.
    Phachonpai W, Wattanathorn J, Muchimapura S, Tong-Un T, Preechagoon D (2010) Neuroprotective effect of quercetin encapsulated liposomes: a novel therapeutic strategy against Alzheimer’s disease. Am J Appl Sci 7:480–485CrossRefGoogle Scholar
  134. 134.
    An Y, Tang L, Jiang X, Chen H, Yang M, Jin L, Zhang S, Wanf C, Zhnag W (2010) A photoelectrochemical immunosensor based on Au-doped TiO2 nanotube arrays for the detection of α-synuclein. Chemistry 16:14439–14446CrossRefGoogle Scholar
  135. 135.
    Hasadsri L, Kreuter J, Hattori H, Iwasaki T, George JM (2009) Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem 284:6972–6981CrossRefGoogle Scholar
  136. 136.
    Klyachko NL, Haney MJ, Zhao Y, Manickam DS, Mahajan V, Suresh P, Hingtgen SD, Mosley RL, Gendelman HE, Kabanov AV, Batrakova EV (2014) Macrophages offer a paradigm switch for CNS delivery of therapeutic proteins. Nanomedicine (Lond.) 9:403–422CrossRefGoogle Scholar
  137. 137.
    Basso AS, Frenkel D, Quintana FJ, Costa-Pinto FA, Petrovic-Stojkovic S, Puckett L, Monsonego A, Bar-Shir A, Engel Y, Gozin M, Weiner HL (2008) Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest 118:1532–1543CrossRefGoogle Scholar
  138. 138.
    Korn T (2008) Pathophysiology of multiple sclerosis. J Neurol 255(Suppl 6):2–6CrossRefGoogle Scholar
  139. 139.
    Hu K, Shi Y, Jiang W, Han J, Huang S, Jiang X (2011) Lactoferrin conjugated PEGPLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson’s disease. Int J Pharm 415:273–283CrossRefGoogle Scholar
  140. 140.
    Papa S, Ferrari R, De Paola M, Rossi F, Mariani A, Caron I, Sammali E, Peviani M, Dell'Oro V, Colombo C, Morbidelli M, Forloni G, Perale G, Moscatelli D, Veglianese P (2014) Polymeric nanoparticle system to target activated microglia/macrophages in spinalcord injury. J Cont Rel 174:15–26CrossRefGoogle Scholar
  141. 141.
    Klyachko NL, Haney MJ, Zhao Y (2013) Macrophages offer a paradigm switch for CNS delivery of therapeutic proteins. Nanomedicine 9:1403–1422CrossRefGoogle Scholar
  142. 142.
    Cheng Y, Morshed RA, Auffinger B, Tobias AL, Lesniak MS (2014) Multifunctional nanoparticles for brain tumor imaging and therapy. Adv Drug Deliv Rev 66:42–57CrossRefGoogle Scholar
  143. 143.
    Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V (2012) PLGA-based nanoparticles: an overview of biomedical applications. J Cont Rel 161:505–522CrossRefGoogle Scholar
  144. 144.
    Cabral H, Kataoka K (2014) Progress of drug-loaded polymeric micelles into clinical studies. J Cont Rel 190:465–476CrossRefGoogle Scholar
  145. 145.
    Guo J, Gao X, Su L, Xia H, Gu G, Pang Z, Jiang X, Yao L, Chen J, Chen H (2011) Aptamer-functionalized PEG–PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 32:8010–8020CrossRefGoogle Scholar
  146. 146.
    Jacobs CB, Ivanov IN, Nguyen MD, Zestos AG, Venton BJ (2014) High temporal resolution measurements of dopamine with carbon nanotube yarn microelectrodes. Anal Chem 86:5721–5727CrossRefGoogle Scholar
  147. 147.
    Lee HJ, Park J, Yoon OJ, Kim HW, Lee DY, Kim DH, Lee WB, Lee NE, Bonventre JV, Kim SS (2011) Amine-modified singlewalled carbon nanotubes protect neurons from injury in a rat stroke model. Nature Nanotechnol 6:121–125CrossRefGoogle Scholar
  148. 148.
    Das S, Carnicer-Lombarte A, Fawcett JW, Bora U (2016) Bio-inspired nano tools for neuroscience. Prog Neurobiol 142:1–22CrossRefGoogle Scholar
  149. 149.
    Da Silva-Candal A, Argibay B, Iglesias-Rey R, Vargas Z, Vieites-Prado A, López-Arias E, Rodríguez-Castro E, López-Dequidt I, Rodríguez-Yáñez M, Piñeiro Y, Sobrino T, Campos F, Rivas J, Castillo J (2017) Vectorized nanodelivery systems for ischemic stroke: a concept and a need. J Nanobiotechnol 15:30CrossRefGoogle Scholar
  150. 150.
    Pramanik M, Swierczewska M, Green D, Sitharaman B, Wang LV (2009) Single-walled carbon nanotubes as a multimodalthermoacoustic and photoacoustic-contrast agent. J Biomed Optic 14:034018CrossRefGoogle Scholar
  151. 151.
    Keberle H (1964) The biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci 119:758–768CrossRefGoogle Scholar
  152. 152.
    Bush AI (2003) The metallobiology of Alzheimer’s disease. Trends Neurosci 26:207–214CrossRefGoogle Scholar
  153. 153.
    Adlard PA, Bush AI (2006) Metals and Alzheimer’s disease. J Alzheimers Dis 10:145–163CrossRefGoogle Scholar
  154. 154.
    Wilson B (2009) Brain targeting PBCA nanoparticles and the blood-brain barrier. Nanomedicine 4:499–502CrossRefGoogle Scholar
  155. 155.
    Lauzon MA, Daviau A, Marcos B, Faucheux N (2015) Nanoparticle mediated growth factor delivery systems: a new way to treat Alzheimer’s disease. J Cont Rel 206:187–205CrossRefGoogle Scholar
  156. 156.
    Popovic N, Brundin P (2006) Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. Int J Pharm 314:120–126CrossRefGoogle Scholar
  157. 157.
    Locatelli E, Franchini MC (2012) Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis, properties, and nanomedical applications as drug delivery system. J Nanopart Res 14:1316CrossRefGoogle Scholar
  158. 158.
    Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE (2001) Biodegradable polymeric nanoparticles as drug delivery devices. J Cont Rel 70:1–20CrossRefGoogle Scholar
  159. 159.
    Pisani MJ, Wheate NJ, Keene FR, Aldrich-Wright JR, Collins JG (2009) Anionic PAMAM dendrimers as drug delivery vehicles for transition metal-based anticancer drugs. J Inorg Chem 103:373–380Google Scholar
  160. 160.
    Kreuter J (2014) Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv Drug Deliv Rev 71:2–14CrossRefGoogle Scholar
  161. 161.
    Jain KK (2012) Nanobiotechnology-based strategies for crossing the blood–brain barrier. Nanomedicine 7:1225–1233CrossRefGoogle Scholar
  162. 162.
    Neha B, Ganesh B, Preeti K (2013) Drug delivery to the brain using polymeric nanoparticles: a review. Int J Pharm Life Sci 2:107–132CrossRefGoogle Scholar
  163. 163.
    Lee K, Solanki A, Kim JD, Jung J (2016) Nanomedicine: dynamic integration of nanotechnology with biomedical sciences; chapter II and Ellis-Behnke R, A small introduction to the world of nanomedicine; chapter III; and Allhoff R, The coming era of nanomedicine, chapter V. In: Bawa R, Audette GF, Rubinstein I (eds) Handbook of clinical nanomedicine: nanoparticles, imaging, therapy, and clinical applications. Pan Standford Publishing, SingaporeGoogle Scholar
  164. 164.
    Di Stefano A, Iannitelli A, Laserra S, Sozio P (2011) Drug delivery strategies for Alzheimer’s disease treatment. Expert Opin Drug Deliv 8:581–603CrossRefGoogle Scholar
  165. 165.
    Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE, Balabanyan VU, Voronina TA, Trofimov SS, Kreuter J, Gelperina S, Begley D, Alyautdin RN (2009) Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target 17:564–574CrossRefGoogle Scholar
  166. 166.
    Thorne RG, Pronk GJ, Padmanabhan V, Frey WH (2004) Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127:481–496CrossRefGoogle Scholar
  167. 167.
    Zhang C, Chen J, Feng C, Shao X, Liu Q, Zhang Q, Pang Z, Jiang X (2014a) Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer’s disease. Int J Pharm 461:192–202CrossRefGoogle Scholar
  168. 168.
    Sozio P, Fiorito J, Di Giacomo V, Di Stefano A, Marinelli L, Cacciatore I, Cataldi A, Pacella S, Turkez H, Parenti C, Rescifina A, Marrazzo A (2014) Haloperidol metabolite II prodrug: asymmetric synthesis and biological evaluation on rat C6 glioma cells. Eur J Med Chem 90:1–9CrossRefGoogle Scholar
  169. 169.
    Gastaldi L, Battaglia L, Peira E, Chirio D, Muntoni E, Solazzi I, Gallarate M, Dosio F (2014) Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. Eur J Pharm Biopharm 87:433–444CrossRefGoogle Scholar
  170. 170.
    Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5:505–515CrossRefGoogle Scholar
  171. 171.
    Nelluri S, Felix JV, Sathesh KS (2015) Formulation and evaluation of galantamine nanoparticles for neurological disorders. Int J Pharm Chem Biol Sci 5:63–70Google Scholar
  172. 172.
    Gregoriadis G (2008) Liposome research in drug delivery: the early days. J Drug Targe 16:520–524CrossRefGoogle Scholar
  173. 173.
    Spuch C, Navarro C (2011) Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer’s disease and Parkinson’s disease). J Drug Deliv 2011:469679CrossRefGoogle Scholar
  174. 174.
    Gobbi M, Re F, Canovi M, Beeg M, Gregori M, Sesana S, Sonnino S, Brogioli D, Musicanti C, Gasco P, Salmona M, Masserini ME (2010) Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. Biomaterials 31:6519–6529CrossRefGoogle Scholar
  175. 175.
    Eckert GP, Chang S, Eckmann J, Copanaki E, Hagl S, Hener U, Müller WE, Kögel D (2011) Liposome-incorporated DHA increases neuronal survival by enhancing non-amyloidogenic APP processing. Biochim Biophys Acta 1808:236–243CrossRefGoogle Scholar
  176. 176.
    Lasagna-Reevesa C, Gonzalez-Romeroa D, Barriaa MA, Olmedoc I, Closa A, Sadagopa Ramanujam VM, Urayama A, Vergara L, Kogan MJ, Soto C (2010) Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochem Biophys Res Commun 393:649–655CrossRefGoogle Scholar
  177. 177.
    Triulzi RC, Dai Q, Zou J, Leblanc RM, Gu Q, Orbulescu J, Huo Q (2008) Photothermal ablation of amyloid aggregates by gold nanoparticles. Colloids Surf B Biointerf 63:200–208CrossRefGoogle Scholar
  178. 178.
    Gamaleia NF, Shishko ED, Dolinsky GA, Shcherbakov AB, Usatenko AV, Kholin VV (2010) Photodynamic activity of hematoporphyrin conjugates with gold nanoparticles. Experiments in vitro. Exp Oncol 32:44–47Google Scholar
  179. 179.
    Marzesco AM, Janich P, Wilsch-Bräuninger M, Dubreuil V, Langenfeld K, Corbeil D, Huttner WB (2005) Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. J Cell Sci 118:2849–2858CrossRefGoogle Scholar
  180. 180.
    Verderio C, Muzio L, Turola E, Bergami A, Novellino L, Ruffini F, Riganti L, Corradini I, Francolini M, Garzetti L, Maiorino C, Servida F, Vercelli A, Rocca M, Dalla Libera D, Martinelli V, Comi G, Martino G, Matteoli M, Furlan R (2012) Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann Neurol 72:610–624CrossRefGoogle Scholar
  181. 181.
    Zhang J, Atay T, Nurmikko AV (2009) Optical detection of brain cell activity using plasmonic gold nanoparticles. Nano Lett 9:519–524CrossRefGoogle Scholar
  182. 182.
    Zhang P, Chen L, Gu W, Xu Z, Gao Y, Li Y (2007) In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer’s disease. Biomaterials 28:1882–1888CrossRefGoogle Scholar
  183. 183.
    Iijima S (1991) Helical microtubules of graphitic carbon. Nature 354:56–58CrossRefGoogle Scholar
  184. 184.
    Kakkar AK, Dahiya N (2015) Management of Parkinson’s disease: current and future pharmacotherapy. Eur J Pharmacol 750:74–81CrossRefGoogle Scholar
  185. 185.
    Folch J, Petrov D, Ettcheto M, Abad S, Sánchez-López E, García ML, Olloquequi J, Beas-Zarate C, Auladell C, Camins A (2016) Current research therapeutic strategies for Alzheimer’s disease treatment. Neural Plasti 2016:8501693CrossRefGoogle Scholar
  186. 186.
    Malarkey EB, Parpura V (2007) Applications of carbon nanotubes in neurobiology. Neurodegener Dis 4:292–299CrossRefGoogle Scholar
  187. 187.
    Fabbro A, Prato M, Ballerini L (2013) Carbon nanotubes in neuroregeneration and repair. Adv Drug Deliv Rev 65:2034–2044CrossRefGoogle Scholar
  188. 188.
    Dugan LL, Lovett EG, Quick KL, Lotharius J, Lin TT, O'Malley KL (2001) Fullerene-based antioxidants and neurodegenerative disorders. Parkinson Rel Disord 7:243–246CrossRefGoogle Scholar
  189. 189.
    Dugan LL, Turetsky DM, Du C, Lobner D, Wheeler M, Almli CR, Shen CK, Luh TY, Choi DW, Lin TS (1997) Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci U S A 94:9434–9439CrossRefGoogle Scholar
  190. 190.
    Tykhomyrov AA, Nedzvetsky VS, Klochkov VK, Andrievsky GV (2008) Nanostructures of hydrated C60 fullerene (C60HyFn) protect rat brain against alcohol impact and attenuate behavioral impairments of alcoholized animals. Toxicology 246:158–165CrossRefGoogle Scholar

Copyright information

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Department of ChemistryAligarh Muslim UniversityAligarhIndia
  2. 2.Department of Biology, College of Natural and Computational SciencesUniversity of GondarGondarEthiopia
  3. 3.Special Infectious Agents Unit, King Fahd Medical Research CenterKing Abdulaziz UniversityJeddahSaudi Arabia
  4. 4.Department of Surgery, College of Medicine and Health SciencesUniversity of GondarGondarEthiopia

Personalised recommendations